

Congress organised by the Heart Failure Association of the ESC

Heart Failure

2017

and 4th World Congress
on Acute Heart Failure

Paris
France

29 April - 2 May

Heart Failure: rendez-vous with the future

www.escardio.org/HFA

#heartfailure2017

Industry
Programme



"I WANT TO FINISH THIS FOR MY GRANDSON,
BUT I'M NOT FEELING UP TO IT"

HFrEF symptoms diminish health-related Quality of Life
and indicate the need to do more¹⁻³



When you see symptoms,
IT'S TIME FOR ENTRESTO⁴



Entresto[®]
sacubitril/valsartan

Join us and discover the
world of a HFrEF patient.

HFrEF = heart failure with reduced ejection fraction.

Please see Summary of Product Characteristics at Booth B30.

▼ This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

References: 1. Heo S, Moser DK, Lennie TA, Fischer M, Smith E, Walsh MN. Modifiable correlates of physical symptoms and health-related quality of life in patients with heart failure: a cross-sectional study. *Int J Nurs Stud.* 2014;51(11): 1482-1490. 2. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. *Eur J Cardiovasc Nurs.* 2005;4(3):198-206. 3. Ponikowski P, Voors A, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2016;37(27):2129-2200. 4. ENTRESTO Summary of Product Characteristics. European Medicines Agency, 2016. <http://www.ema.europa.eu>.

Building Overview




Table of Contents

Exhibition

List of Exhibitors by Product Category	8
Exhibition Floor Plan	9
Company and Product Descriptions	10

Industry Sponsored Sessions

Satellite Symposia	18
Satellite Symposia - Experts on the Spot	21
Hands-On Tutorials	22

Welcome Address

As the world's largest and most influential meeting on heart failure, Heart Failure 2017 & the World Congress on Acute Heart Failure maintains its position as an important platform for scientific exchange and networking. The congress is an integral part of the mission of the Heart Failure Association (HFA) of the ESC which works hard to improve quality of life and longevity for patients, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

This year's main theme 'rendez-vous with the future' aims to educate by offering sessions on all areas of heart failure, bringing the future of heart failure research to the forefront with the Late Breaking Trials sessions and the enormous selection of oral and poster abstracts.

The science and research from our select industry partners is an integral part of the educational offer we have constructed for the congress which we invite you to discover in this programme.

Discover the opportunities that the HFA has to offer on stand B20 in the Exhibition.

Alexandre Mebazaa
Heart Failure 2017 Chairperson

Frank Ruschitzka
HFA President



MILLIONS OF PEOPLE IN THE WORLD HAVE HEART FAILURE

ONE WEBSITE CAN HELP THEM UNDERSTAND THEIR CONDITION
AND TAKE THE NECESSARY STEPS TO LIVE FULL AND ACTIVE LIVES



EXPLORE THE SITE TO FIND OUT ABOUT :

- ! **WHAT ARE THE WARNING SIGNS ?**
- ✓ **ADVICE ON WHAT YOU CAN DO**
- ⤵ **HELPING YOU UNDERSTAND HEART FAILURE**
- 😊 **TIPS FOR LIVING WITH HEART FAILURE**

WWW.HEARTFAILUREMATTERS.ORG

- 😊 **CAPTIVATING ANIMATIONS**
- 📺 **PERSONAL EXPERIENCE VIDEOS**
- 👤 **PRACTICAL PATIENT INFORMATION**
- 📄 **DOWNLOADABLE TOOLS**

This website is available in numerous languages



FOLLOW US
ON FACEBOOK



EUROPEAN
ASSOCIATION
OF CARDIOLOGY*

In this document you will find more information regarding industry at Heart Failure 2017 & World Congress on Acute Heart Failure. Our industry partners are at the very heart of patient care, providing you with the necessary data on products and resources to facilitate your daily practice and improve patient outcomes. The very latest cardiovascular developments will be discussed and debated during the congress – make sure you share in this experience by attending the following:

Exhibition (see page 8)

The exhibition is an integral part of the congress. The exhibition provides delegates with the opportunity to exchange with key industry experts on critical areas of development, research in cardiovascular products and therapies. The exhibition will be a central hub for scientific discussion and exchange during the congress.

Satellite Symposia (see page 18)

Delegates are cordially invited to attend a series of Satellite Symposia included in the congress scientific programme. These sessions will offer pertinent data on the latest scientific information and developments from the industry.

Satellite Symposia - Experts on the Spot (see page 21)

These sessions provide delegates attending or interested in Satellite Symposia with a further opportunity to question and exchange with topic experts in a concise and interactive format on the session content. These short 30 minutes sessions will be arranged in two AGORA designed to ensure experts interact with delegates.

Hands-On Tutorials (see page 22)

Hands-On Tutorials offer delegates a unique opportunity for practical training and hands-on learning from industry experts in an intimate setting, allowing them to address specific issues essential to their daily practice. Sign up in the tutorial rooms or at sponsors' stands.

SEARCH
by keywords

NEWS

ACCESS
your final programme,
maps, speakers...

CREATE
your personal
programme



VOTE
& ask
questions

Search for 'Heart Failure 2017' in App Store® / Google play



The Heart Failure 2017 Mobile App is supported by SERVIER in the form of an unrestricted educational grant.



EXHIBITION

OPENING HOURS

Saturday 29 April 10:00 – 18:00

Sunday 30 April 09:00 – 18:00

Monday 1 May 09:00 – 18:00

Tuesday 2 May **CLOSED**

List of Exhibitors by Product Category

Antiarrhythmia

ZOLL LifeVest **B41**

Anticoagulants

Bayer AG **C20**
BMS Pfizer Alliance **B10**

Antidiabetic Agents

AstraZeneca **B50**

Antiplatelet Agents

AstraZeneca **B50**
Bayer AG **C20**

Blood Pressure Measurement Equipment

AtCor Medical **C60**

Cardiac Resynchronisation

Abbott **B90/91**
BIOTRONIK SE & Co. KG **B60**
Impulse Dynamics **C30**
Medtronic **C35**

Cardiac Stimulant

Orion Pharma **C21**

Cardiomyopathy

Alere International Ltd **B80**
GICC (French Working Group of Heart Failure) **B25**

Clinical Database & Research

Wiley **C34**

Clinical Laboratory & Testing Services

Alere International Ltd **B80**
Roche Diagnostics International Ltd. **A20**
THERMO FISHER SCIENTIFIC **B95**

Defibrillators

Medtronic **C35**
ZOLL LifeVest **B41**

Education/Teaching Aids

PACE-CME: Physicians' Academy for Cardiovascular Education **A40**
Wiley **C34**

Electrophysiology

Impulse Dynamics **C30**

Instrumentation

Alere International Ltd **B80**
AstraZeneca **B50**
Critical Diagnostics **A30**

In Development

AstraZeneca **B50**
Prothena Corporation plc **C55**

Inodilator

Orion Pharma **C21**

Inotrope

Orion Pharma **C21**

Iron Therapy

Vifor Pharma **C10**

Non-Invasive Monitor/Testing

AtCor Medical **C60**
Critical Diagnostics **A30**

Non-profit Organisation

European Society of Cardiology (ESC) **B20**
GICC (French Working Group of Heart Failure) **B25**
Heart Failure Association (HFA) of the ESC **B20**
PACE-CME: Physicians' Academy for Cardiovascular Education **A40**

Pacemakers & Pacing Systems

BIOTRONIK SE & Co. KG **B60**
CVRx Inc. **A50**

Patient Monitoring System

Abbott **B90/91**
BIOTRONIK SE & Co. KG **B60**
Medtronic **C35**

Publishers/Books/Journals

Wiley **C34**
Wisepress Medical Bookshop **C01**

Resuscitation

ZOLL LifeVest **B41**

Transcatheter Devices

Abbott **B90/91**

Vascular Therapies

Bayer AG **C20**

Exhibition Floor Plan



Company and Product Descriptions

Abbott

St. Jude Medical (Abbott)

Da Vincilaan 11
1935 Zaventem, Belgium
Tel: +32 277 468 69
Email: mderaedt@sjm.com

Abbott, Structural Heart

Park Lane, Culliganlaan 2B
1831 Diegem, Belgium
Tel: +32 271 414 11
Email: EMEA.SH@abbott.com
Website: www.abbott.com

Product Categories: Cardiac Resynchronisation
Patient Monitoring System
Transcatheter Devices

At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

Abiomed Europe GmbH

Neuenhofer Weg 3, 52074 Aachen, Germany
Email: vborgmann@abiomed.com - Website: www.protectedpci.eu
Abiomed is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. CEO, Chairman, and President Michael R. Minogue has focused the company's efforts on developing ground-breaking technologies designed to improve the patient outcomes focused on native heart recovery. Founded in 1981 for the purpose of developing the world's first artificial heart, Abiomed has remained dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

B90/B91

Alere International Ltd

Parkmore East Business Park, Ballybrit, Galway, Ireland
Tel: +44 123 475 9934

Email: events@alere.com - Website: www.alere.com

Product Categories: Cardiomypathy
Clinical Laboratory & Testing Services
Instrumentation

Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers on this vision by providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit www.alere.com.

Alnylam Pharmaceuticals

300 Third Street # 3, Cambridge
MA 02142, United States of America
Tel: +1 617 551 8200 - Fax: +1 617 551 8101
Email: info@alnylam.com - Website: www.alnylam.com

Alnylam is developing an entirely new class of medicines based on the breakthrough discovery in biology known as RNA interference, or RNAi. Alnylam believes that RNAi therapeutics is a promising approach to silence disease-causing genes, and represent an opportunity to transform the treatment of many diseases.

B80

C65



AstraZeneca

1 Francis Crick Avenue, Cambridge Biomedical Campus
CB2 0AA Cambridge
Tel: +44 203 749 5000
Website: www.astrazeneca.com

Product Categories: [Antidiabetic Agents](#)
 [Antiplatelet Agents](#)
 [In Development](#)

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AtCor Medical

Unit 11, West Ryde Corporate Centre
1059-1063 Victoria Road
West Ryde, NSW 2114, Australia
Tel: +61 2 987 487 61 - Fax: +61 2 987 490 22
Email: contact.europe@atcormedical.com - Website: www.atcormedical.com

Product Categories: [Blood Pressure Measurement Equipment](#)
 [Non-Invasive Monitor/Testing](#)

Higher aortic stiffness (measured by aortic pulse wave velocity) has been shown to be associated with a significantly increased risk of developing heart failure in the future. The SphygmoCor® XCEL system, an easy-to-use cuff based system, provides PWV measurements in only 1 minute.
Visit us at our booth.

Bayer AG

Müllerstr. 178, 13353 Berlin, Germany
Tel: +49 304 681 111 - Fax: +49 304 681 530
Email: info@bayer.com - Website: www.bayer.com

Product Categories: [Anticoagulants](#)
 [Antiplatelet Agents](#)
 [Vascular Therapies](#)

B50

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. For more information, go to www.bayer.com

BIOTRONIK SE & Co. KG

Woermannkehe 1
12359 Berlin, Germany
Tel: +49 306 890 50 - Fax: +49 306 844 060
Email: info@biotronik.com - Website: www.biotronik.com

Product Categories: [Cardiac Resynchronisation](#)
 [Pacemakers & Pacing Systems](#)
 [Patient Monitoring System](#)

BIOTRONIK champions cardiovascular and endovascular solutions that deliver care and instill confidence. For over 50 years, we have been a dedicated partner to healthcare providers, committed to improvements that patients deserve. Caring beyond the implant completes the circle of BIOTRONIK's CRT solutions. Recent studies show BIOTRONIK Home Monitoring® saves lives by slowing heart failure progression.

BMS Pfizer Alliance

Email: eva.mccartney2@pfizer.com
Product Category: [Anticoagulants](#)

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer's global scale and expertise in this field.

Charité Universitätsmedizin Berlin

Augustenburger Platz 1
13353 Berlin, Germany
Tel: +49 304 505 534 07 - Fax: +49 304 505 539 51
Website: www.charite.de/en

C60

C20

B60

B10

B96

Company and Product Descriptions

Critical Diagnostics

A30

3030 Bunker Hill Street, Suite 117A

San Diego, CA 92109

United States of America

Tel: +1 858 270 2448

Email: info@criticaldiagnostics.com - Website: www.criticaldiagnostics.com

Product Categories: Instrumentation
 Non-Invasive Monitor/Testing

Soluble ST2 has now been published in more than 400 peer-reviewed articles and scientific posters studying more than 36,000 patients. These clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death in chronic heart failure. They have further shown that the prognostic information from soluble ST2 is independent and provides added information to the cardiac biomarkers commonly used today, including the natriuretic peptides, BNP and NT-proBNP.

CVRx Inc.

A50

9201 West Broadway Avenue, Suite 650

Minneapolis, MN 55445

United State of America

Tel: +1 763 416 2840

Email: jpzana@cvr.com - Website: www.barostimtherapy.com

Product Category: Pacemakers & Pacing Systems

CVRx® developed a proprietary implantable technology for the treatment of high blood pressure and heart failure: the BAROSTIM NEO. It uses CVRx-patented technology that is designed to trigger the body's own natural blood flow regulation system to treat these conditions. BAROSTIM NEO can be adjusted to meet each patient's individual therapy needs.

BAROSTIM NEO is CE-marked in Europe for the treatment of heart failure with reduced left ventricular ejection fraction. It is also CE-marked in Europe for the treatment of resistant hypertension.

European Society of Cardiology (ESC)

B20

2035 Route des Colles, Les Templiers, CS 801 79 Biot, 06903 Sophia Antipolis, France
Tel : +33 4 92 94 86 69

Email: communications@escardio.org - Website: www.escardio.org

Product Category: Non-profit Organisation

The European Society of Cardiology (ESC) comprises 56 National Cardiac Societies from Europe and the Mediterranean basin, 15 Working Groups, 6 Associations, 6 Councils and the distinguished community of ESC Fellows. These constituent bodies make up the ESC membership of over 96 000 cardiology professionals.

To fulfil its mission of "reducing the burden of cardiovascular disease", the ESC provides scientific and educational activities and products, such as Clinical Practice Guidelines, educational courses and material, registries on specific disease areas and the organisation of major cardiology congresses.

GICC (French Working Group of Heart Failure)

B25

SFC 5 rue des Colles, 75012 Paris, France

Tel: +33 3 20 44 57 21

Email: pascal.degroot@chru-lille.fr

Product Categories: Cardiomyopathy
 Non-profit Organisation

Heart Failure Association (HFA) of the ESC

B20

2035 Route des Colles, Les Templiers, CS 801 79 Biot, 06903 Sophia Antipolis, France
Tel: +33 4 92 94 76 00

Websites: www.escardio.org/HFA - www.heartfailurematters.org

Product Category: Non-profit Organisation

Mission: To improve quality of life and longevity through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

Discover the HFA's opportunities in membership, research, education and advocacy.

Impulse Dynamics

C30

Breitwiesenstraße 19, 70565 Stuttgart, Germany
Tel: +49 711 220 456 17 - Fax: +49 711 220 456 19

Email: c.jaschko@impulse-dynamics.com - Website: www.impulse-dynamics.com

Product Categories: [Cardiac Resynchronisation](#)
[Electrophysiology](#)

Impulse Dynamics, a member of the Hobart Group of companies, is focused on the development of electrical therapies for the treatment of chronic heart failure. As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the United States, Europe, Asia and Australia. For more information, please visit www.impulse-dynamics.com.

The Optimizer Smart device, which delivers CCM therapy, has been successfully launched in Europe and is available in a growing number of cardiology centers. Over 3,000 patients worldwide have already received CCM through the Optimizer III or IVs device, the only device therapy available for patients with a narrow QRS complex. Impulse Dynamics has completed extensive clinical studies, including several randomized controlled trials, published in articles in over 60 leading medical journals. The Optimizer Smart is not currently approved for use in the United States; the Optimizer IVs, an earlier version of the device, is approved in the United States for investigational use only.

Medtronic

C35

31 Route du Molliau, 1131 Tolochenaz, Switzerland

Tel: +41 218 027 000

Email: christine.dettwiler@medtronic.com - Website: www.medtronic.eu

Product Categories: [Cardiac Resynchronisation](#)
[Defibrillators](#)
[Patient Monitoring System](#)

Through innovation and collaboration, Medtronic improves the lives and health of millions of people each year.

Join our symposium "Implantable cardiac device therapy for heart failure: Update 2017" on April 30, 12:45 - 14:00 (room Zola) and come to our booth C35 to discover our therapies and solutions in Heart Failure management across the Continuum of Care - Identify, Treat & Manage your patients.

Let's take healthcare Further, Together. Learn more about our technology, services and solutions at www.medtronic.eu.

Novartis Pharma AG

B30/B40

Forum I, Novartis Campus
CH-4056 Basel, Switzerland

Tel: +41 613 241 111 - Fax: +41 613 248 001

Email: media.relations@novartis.com - Website: www.novartis.com

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion (USD 8.4 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit <http://www.novartis.com>

Orion Pharma

C21

Orionintie 1 A
02200 Espoo, Finland

Tel: +358 104 261

Email: web.simdax@orionpharma.com - Website: www.orionpharma.com

Product Categories: [Cardiac Stimulant](#)
[Inodilator](#)
[Inotrope](#)

Orion is a globally operating pharmaceutical company, founded in Finland in 1917. Orion Pharma's proprietary drug levosimendan (SIMDAX®) is a unique inodilator with sustained hemodynamic effects and symptom control which was developed to treat patients with acute heart failure, and patients in need of inotropic therapy. The mechanism of action of SIMDAX® does not evoke an increase of oxygen consumption in the myocardium. SIMDAX® has been proven effective and well tolerated in several randomized clinical trials in a total of over 7000 patients. Up to date, over 1 million patients in 60 countries worldwide have been treated with SIMDAX®.

Company and Product Descriptions

PACE-CME: Physicians' Academy for Cardiovascular Education

A40

Po Box 916, 2003RX Haarlem, The Netherlands

Tel: +31 235 317 357 - Fax: +31 235 317 271

Email: info@pace-cme.org - Website: www.PACE-CME.org

Product Categories: Education/Teaching Aids
Non-profit Organisation

PACE-CME: Physicians' Academy for Cardiovascular Education is a foundation established to meet the need for high-quality education. The rationale for establishing PACE-CME comes from the recognition that physician education plays an increasingly important role in our efforts to reduce the global burden of cardiovascular disease. PACE-CME is an initiative of renowned experts in different areas of cardiovascular disease. Since its inception, PACE-CME has initiated a large number of educational activities around the world.

Prothena Corporation plc

C55

Adelphi Plaza, Upper George's Street, Dún, A96 T927 Laoghaire Dublin, Ireland

Tel: +353 1 236 2500 - Fax: +353 1 902 351

Email: info@prothena.com - Website: www.prothena.com

Product Category: In Development

Prothena Corporation plc is a global, late-stage biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding in protein misfolding and cell adhesion - the root causes of many serious or currently untreatable amyloid and inflammatory diseases - Prothena has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of product candidates targets potential indications including AL amyloidosis (NEOD001), Parkinson's disease (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more information, visit www.prothena.com.

Roche Diagnostics International Ltd.

A20

Forrenstrasse 2, 6343 Rotkreuz, Switzerland

Email: global.congress.gcl@roche.com - Website: www.roche.com

Product Category: Clinical Laboratory & Testing Services

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. In cardiology, Roche Diagnostics offers a wide range of tests to help in the rapid and accurate diagnosis of diseases such as acute coronary syndrome and heart failure.

Heart failure is a global health challenge associated with high morbidity and mortality. Detection in its early stages and appropriate treatment are key objectives in improving quality of life. Roche NT-proBNP plays a significant role in improving clinical-decision making from diagnosis to monitoring of heart failure in laboratories, as well as at the Point-of-Care.

SERVIER

B45

50 Rue Carnot, 92284 Suresnes Cedex, France

Tel: +33 1 55 72 60 37

Email: sophie.nisse-durgeat@servier.com - Website: www.servier.com

About Servier

Servier is an international pharmaceutical company governed by a foundation and headquartered in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs over 21 000 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of Servier's products turnover in research and development and uses all its profits for growth.

A key player in cardiology and hypertension for the last 20 years, Servier has 12 major products on the market, totaling a turnover of more than 1.6 billion euro in 2016. Currently, there are 12 new fixed-dose combinations and 10 new molecular entities in research or development phase, mainly targeting heart failure. This portfolio of innovative treatments is being developed with partners worldwide.

St. Jude Medical

St. Jude Medical is now Abbott

B90/B91

THERMO FISHER SCIENTIFIC

B95

Neuendorfstrasse 25

16761 Hennigsdorf, Germany

Tel: +49 330 288 30 - Fax: +49 330 288 310

Email: Info.brahms@thermofisher.com - Website: www.thermofisher.com/brahms

Product Category: [Clinical Laboratory & Testing Services](#)

B•R•A•H•M•S GmbH, part of Thermo Fisher Scientific, investigates, develops and manufactures novel diagnostic testing procedures to improve early diagnosis and treatment of life threatening diseases. With high-quality immunodiagnostic tests for prenatal screening, cardiovascular, pulmonary, and cancer disorders as well as particularly for sepsis, the company contributes to the creation of a healthier future – to the greatest advantage for medical professionals and patients.

B•R•A•H•M•S GmbH is leading in specific market places and therapeutic areas. The aim of its basic research is to identify new biomarkers, with support by international co-operations and reputable research institution.

Vifor Pharma

C10

Flughofstrasse 61

CH-8152 Glattbrugg, Switzerland

Tel: +41 588 518 000 - Fax: +41 588 518 001

Email: info@viforpharma.com - Website: www.viforpharma.com

Product Category: [Iron Therapy](#)

Vifor Pharma is a fully integrated, Swiss specialty pharmaceutical company and part of the Galenica Group. Vifor Pharma is a global leader in the development, production and marketing of innovative products for the treatment of iron deficiency, with or without anaemia, a widespread condition. At Vifor Pharma we aim to have a positive impact on the lives of patients and consumers by continuously building on our expertise in iron deficiency, infectious diseases and nephrology.

Wiley

C34

The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, United Kingdom
Tel: +44 124 384 3291

Email: customer@wiley.com - Website: www.onlinelibrary.wiley.com

Product Categories: [Clinical Database & Research](#)
[Education/Teaching Aids](#)
[Publishers/Books/Journals](#)

Wiley is a global business that helps people and organizations to develop the skills and knowledge they need to succeed. See our cardiology digital content, books and journals, including the leading Heart Failure journal - European Journal of Heart Failure and the Open Access journal ESC Heart Failure (the official journals of the HFA of the ESC). Come and see what's new, what's not to be missed and how we can help increase the academic and professional impact of your work.

Wisepress Online Bookshop

C01

15 Lyon Road, SW19 2RL Merton, London, United Kingdom

Tel: +44 208 715 181

Email: marketing@wisepress.com - Website: www.wisepress.com

Product Category: [Publishers/Books/Journals](#)

Wisepress.com, Europe's leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.

ZOLL LifeVest

B41

Emil-Hoffmann-Str. 13, 50996 Köln, Germany

Tel: +49 223 687 8714

Email: cwolves@zoll.com - Website: www.lifevest.zoll.com

Product Categories: [Antiarrhythmia](#)
[Defibrillators](#)
[Resuscitation](#)

ZOLL, an Asahi Kasei Group company, is focused on improving outcomes with novel resuscitation and acute critical care technology. Our product LifeVest is the first wearable defibrillator: It's a treatment option for sudden cardiac arrest that offers patients advanced protection and monitoring as well as improved quality of life.

Ready for an enhanced eLearning experience?

Continuing medical education accredited by EBAC

- Over 20 modules available
- Accredited by EACCME
- State of the art presentations
- Based on Heart Failure Curriculum and Guidelines
- Content written by internationally renowned experts
- Case studies
- 3D animations



Exclusively for HFA Silver, Gold and Fellow Members

Join the HFA

www.escardio.org/HFA-membership



ESC eLEARNING PLATFORM

www.escardio.org/learnHFA



INDUSTRY SPONSORED SESSIONS

Satellite Symposia
Satellite Symposia - Experts on the Spot
Hands-On Tutorials

Satellite Symposia

Saturday 29 April

12:15-13:15 Room HUGO

Advancing acute heart failure treatment - quo vadis?

Sponsored by **Novartis**

Don't miss the complementary Satellite Symposium - Experts on the Spot session scheduled on Sunday 30 April, 15:55-16:25 in AGORA 1

13:30-14:30 Room HUGO

Journey of a heart failure patient: similarities and differences across the world

Sponsored by **SERVIER**

Don't miss the complementary Satellite Symposia - Experts on the Spot sessions scheduled on Sunday 30 April and on Monday 1 May, 10:15-10:45 in AGORA 1

12:15-13:15 Room ZOLA

Furosemide 2.0 - Subcutaneous administration of a novel formulation

Sponsored by **scPharmaceuticals, Inc.**

Don't miss the complementary Satellite Symposium - Experts on the Spot session scheduled on Sunday 30 April, 10:15-10:45 in AGORA 2

12:15-13:15 Room RENOIR

Heart failure with reduced ejection fraction and narrow QRS: how baroreflex stimulation help?

Sponsored by **Charité Universitätsmedizin Berlin**

13:30-14:30 Room RENOIR

Novel transcatheter options for functional mitral regurgitation in heart failure

Sponsored by **Charité Universitätsmedizin Berlin**

12:15-13:15 Room MATISSE

Treating Functional Mitral Regurgitation (FMR) in heart failure with Transcatheter Mitral Valve Repair (TMVR): rendez-vous with the future now!

Sponsored by **ABBOTT STRUCTURAL HEART**

13:30-14:30 Room MATISSE

New opportunities for an old problem: lowering potassium to maximize heart failure therapy

Organised by **Lorraine University**, supported by an unrestricted educational grant from **AstraZeneca**

12:15-13:15 Room PIAF

Updates on risk guided stratification for primary prevention of sudden cardiac death in heart failure

Sponsored by **GE Healthcare**

13:30-14:30 Room PIAF

NT-proBNP: the gold standard biomarker in heart failure

Sponsored by **Roche Diagnostics International Ltd.**

Don't miss the complementary Satellite Symposium - Experts on the Spot session scheduled on Sunday 30 April, 15:55-16:25 in AGORA 2

Sunday 30 April

12:45-14:00 Room HUGO

Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)

Sponsored by Novartis

12:45-14:00 Room MONET

Management of co-morbidities in heart failure - Exploring new frontiers

Sponsored by Bayer AG

12:45-14:00 Room ZOLA

Implantable cardiac device therapy for heart failure: update 2017

Sponsored by Medtronic

12:45-13:45 Room RENOIR

A mitochondrial approach to heart failure

Sponsored by Charité Universitätsmedizin Berlin

12:45-14:00 Room MATISSE

Iron deficiency in patients with heart failure: time for action

Sponsored by Vifor Pharma

Don't miss the complementary Satellite Symposium - Experts on the Spot session scheduled on Monday 1 May, 10:15-10:45 in AGORA 2

12:45-13:45 Room PIAF

Beat as one: a multidisciplinary approach to treating heart failure

Sponsored by St. Jude Medical is now Abbott

18:15-19:15 Room PIAF

How innovative percutaneous Ventricular Assist Device (pVAD) systems improve outcomes in cardiogenic shock and facilitate complete revascularization in high risk Percutaneous Coronary Intervention (PCI) patients

Sponsored by Abiomed GmbH

Satellite Symposia

Monday | May

12:45-14:00 Room HUGO

The wearable cardioverter defibrillator: an essential tool in the management of patients at high risk for sudden cardiac death

Sponsored by **ZOLL**

12:45-13:45 Room MONET

Heart failure, diabetes, and renal dysfunction: time for a more unified approach

Organised by *Physicians Academy for Cardiovascular Education*, supported by an unrestricted educational grant from *Boehringer-Ingelheim and Lilly*

Don't miss the complementary Satellite Symposium - Experts on the Spot session scheduled on Monday 1 May, 15:55-16:25 in AGORA 2

12:45-13:45 Room ZOLA

Heart failure: what is the potential of SGLT2 inhibition?

Sponsored by **AstraZeneca**

12:45-13:45 Room RENOIR

Tricuspid regurgitation in heart failure: how to treat it?

Sponsored by **Charité Universitätsmedizin Berlin**

12:45-14:00 Room MATISSE

Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASI) therapy in cardio-renal patients by controlling potassium levels


Sponsored by **Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma**

Don't miss the complementary Satellite Symposium - Experts on the Spot session scheduled on Monday 1 May, 15:55-16:25 in AGORA 1

12:45-13:45 Room PIAF

Understanding congestion: thinking beyond diuretic therapy

Sponsored by **Fresenius Medical Care**



Satellite Symposia - Experts on the Spot

Sunday 30 April

10:15-10:45 AGORA 1

The concept of timing in the therapeutic algorithm for chronic heart failure

Sponsored by **SERVIER**

Please refer to the Satellite Symposium scheduled on

Saturday 29 April, 13:30-14:30 in room HUGO

10:15-10:45 AGORA 2

Furosemide 2.0 - Subcutaneous administration of a novel formulation

Sponsored by **scPharmaceuticals**

Please refer to the Satellite Symposium scheduled on

Saturday 29 April, 12:15-13:15 in room ZOLA

15:55-16:25 AGORA 1

Optimising treatment of heart failure – Where are we today?

Sponsored by **Novartis**

Please refer to the Satellite Symposium scheduled on

Saturday 29 April, 12:15-13:15 in room HUGO

15:55-16:25 AGORA 2

Role of biomarkers to prevent heart failure development in diabetes patients

Sponsored by **Roche Diagnostics International Ltd.**

Please refer to the Satellite Symposium scheduled on

Saturday 29 April, 13:30-14:30 in room PIAF

Monday 1 May

10:15-10:45 AGORA 1

Managing heart failure patients in day-to-day practice

Sponsored by **SERVIER**

Please refer to the Satellite Symposium scheduled on

Saturday 29 April, 13:30-14:30 in room HUGO

10:15-10:45 AGORA 2

Iron deficiency in patients with heart failure: implementing the guidelines in your clinical practice

Sponsored by **Vifor Pharma**

Please refer to the Satellite Symposium scheduled on

Sunday 30 April, 12:45-14:00 in room MATISSE

15:55-16:25 AGORA 1

Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels

Sponsored by **Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma**

Please refer to the Satellite Symposium scheduled on

Monday 1 May, 12:45-14:00 in room MATISSE

15:55-16:25 AGORA 2

Heart failure, diabetes, and renal dysfunction: time for a more unified approach

Sponsored by **PACE-CME - Boehringer-Ingelheim/Lilly**

Please refer to the Satellite Symposium scheduled on

Monday 1 May, 12:45-13:45 in room MONET

Hands-on Tutorials

Registrations are recommended at the sponsor booth or in front of the rooms.

I. Sponsored by Abbott/GE Healthcare

HANDS-ON ROOM I

Sunday 30 April

08:30-09:15	<i>Treating mitral regurgitation in heart failure patient: from diagnosis to follow-up</i>
09:30-10:00	<i>How to assess mitral valve and mitral regurgitation with transthoracic echocardiographic ultrasound</i>
10:00-10:30	<i>Transcatheter mitral valve repair device</i>
11:00-11:45	<i>Treating mitral regurgitation in heart failure patient: from diagnosis to follow-up</i>
12:00-12:30	<i>How to assess mitral valve and mitral regurgitation with transthoracic echocardiographic ultrasound</i>
12:30-13:00	<i>Transcatheter mitral valve repair device</i>
14:00-14:45	<i>Treating mitral regurgitation in heart failure patient: from diagnosis to follow-up</i>
15:00-15:30	<i>How to assess mitral valve and mitral regurgitation with transthoracic echocardiographic ultrasound</i>
15:30-16:00	<i>Transcatheter mitral valve repair device</i>
16:30-17:10	<i>Using ramp studies in assist device patients: theory and evidence</i>
17:10-18:00	<i>Left ventricular assist device: performing a ramp study using echocardiographic guidance</i>

Monday 1 May

08:30-09:15	<i>Treating mitral regurgitation in heart failure patient: from diagnosis to follow-up</i>
09:30-10:00	<i>How to assess mitral valve and mitral regurgitation with transthoracic echocardiographic ultrasound</i>
10:00-10:30	<i>Transcatheter mitral valve repair device</i>
11:00-11:45	<i>Treating mitral regurgitation in heart failure patient: from diagnosis to follow-up</i>
12:00-12:30	<i>How to assess mitral valve and mitral regurgitation with transthoracic echocardiographic ultrasound</i>
12:30-13:00	<i>Transcatheter mitral valve repair device</i>
14:00-14:45	<i>Treating mitral regurgitation in heart failure patient: from diagnosis to follow-up</i>
15:00-15:30	<i>How to assess mitral valve and mitral regurgitation with transthoracic echocardiographic ultrasound</i>
15:30-16:00	<i>Transcatheter mitral valve repair device</i>
16:30-17:10	<i>Using ramp studies in assist device patients: theory and evidence</i>
17:10-18:00	<i>Left ventricular assist device: performing a ramp study using echocardiographic guidance</i>

2. Sponsored by Orion Pharma

HANDS-ON ROOM 2

Sunday 30 April

09:00-09:30	<i>Repetitive use of inodilators in advanced heart failure - The rationale</i>
09:30-10:00	<i>Repetitive use of inodilators in advanced heart failure - The scientific evidence</i>
10:00-10:30	<i>Repetitive use of inodilators in advanced heart failure - The clinical practice</i>
11:15-11:45	<i>Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? What is available</i>
11:45-12:15	<i>Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? The therapeutic needs</i>
12:15-12:45	<i>Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? The clinical practice</i>
14:00-14:30	<i>Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF) - Cardiorenal syndrome</i>
14:30-15:00	<i>Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF) - Therapeutic options: what, when and why</i>
15:00-15:30	<i>Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF)</i>
16:15-16:45	<i>Inotropes in acute heart failure: from guidelines to practical use - The ESC guidelines in practice</i>
16:45-17:15	<i>Inotropes in acute heart failure: from guidelines to practical use - Patients in need of inotropes</i>
17:15-17:45	<i>Inotropes in acute heart failure: from guidelines to practical use - How to treat such patients</i>

Monday 1 May

09:00-09:30	<i>Repetitive use of inodilators in advanced heart failure - The rationale</i>
09:30-10:00	<i>Repetitive use of inodilators in advanced heart failure - The scientific evidence</i>
10:00-10:30	<i>Repetitive use of inodilators in advanced heart failure - The clinical practice</i>
11:15-11:45	<i>Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? What is available</i>
11:45-12:15	<i>Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? The therapeutic needs</i>
12:15-12:45	<i>Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? The clinical practice</i>
14:00-14:30	<i>Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF) - Cardiorenal syndrome</i>
14:30-15:00	<i>Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF) - Therapeutic options: what, when and why</i>
15:00-15:30	<i>Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF)</i>
16:15-16:45	<i>Inotropes in acute heart failure: from guidelines to practical use - The ESC guidelines in practice</i>
16:45-17:15	<i>Inotropes in acute heart failure: from guidelines to practical use - Patients in need of inotropes</i>
17:15-17:45	<i>Inotropes in acute heart failure: from guidelines to practical use - How to treat such patients</i>

Sunday 30 April

13:00-14:30 *Time is muscle in acute heart failure: diagnose, treat and prevent!*

15:00-17:00 *Lay hands on our point-of-care solutions*

Monday 1 May

13:00-14:30 *Best practise for discharge and follow up of patients hospitalised with acute heart failure: role of natriuretic peptides and point-of-care testing*

15:00-17:00 *Lay hands on our point-of-care solutions*





Novartis Satellite Symposia
at Heart Failure 2017 &
4th World Congress on
Acute Heart Failure

Advancing acute heart failure treatment – quo vadis?

12:15–13:15 Saturday 29 April 2017
Hugo Room, Le Palais des Congrès de Paris

Chairs: Alexandre Mebazaa (France) and John McMurray (UK)

**Turn over the page
to view the full agenda**



This Satellite Symposium is organised and funded by Novartis Pharma AG
© 2017 Novartis Pharma AG, CH-4002 Basel | March 2017 | GLCM/HTF/0345

Advancing acute heart failure treatment – quo vadis?

Novartis Satellite Symposia
at Heart Failure 2017 &
4th World Congress on
Acute Heart Failure

12:15–13:15 Saturday 29 April 2017

Hugo Room, Le Palais des Congrès de Paris

Chairs: Alexandre Mebazaa (France) and John McMurray (UK)

	Topic	Faculty
12:15–12:18	Welcome and introduction	Alexandre Mebazaa (France) and John McMurray (UK)
12:18–12:36	Acute heart failure drug development: challenges and learnings	John McMurray (UK)
12:36–12:56	Recent and future developments in acute heart failure therapies	John Teerlink (USA)
12:56–13:13	Improving outcomes in acute heart failure: quo vadis? – Panel discussion with audience Q&A interaction	Alexandre Mebazaa (France), John McMurray (UK) and John Teerlink (USA)
13:13–13:15	Summary and key learning points	John McMurray (UK)

Paris, France
29 April - 2 May, 2017



**Saturday,
April 29, 2017**

Room Hugo
13.30-14.30

Scientific programme

Journey of a heart failure patient: similarities and differences across the world

Chairpersons:

M. Cowie (UK) and **M. Komajda** (France)

Introduction

M. Komajda (France)

Illustrating the heart failure patient's journey

M. Cowie (UK)

Panel discussion on optimizing heart failure care

Views from around the world

Moderator: **M. Cowie** (UK)

Speakers: **M. Hassanein** (Egypt), **Y. Lopatin** (Russia),
A. Margonato (Italy), **E. Reyes** (Philippines),
C. Saldarriaga (Colombia)

Conclusion

M. Cowie (UK)

Satellite Symposium held during the Heart Failure Congress Paris and organized by





We are committed to therapeutic progress **to serve patients' needs**


An international pharmaceutical group, governed by a foundation, with a firm resolve to innovate
21 000 staff in 148 countries, 3 research centers, 15 production sites
25% of turnover (excluding generics) invested in R&D

5 R&D areas

Cardiovascular disease • Diabetes • Cancer • Immuno-inflammatory disease • Neurodegenerative disease



www.servier.com



scPharmaceuticals Satellite Symposium

HEART FAILURE 2017 & 4TH WORLD
CONGRESS ON ACUTE HEART FAILURE

Furosemide 2.0 – Subcutaneous Administration of a Novel Formulation

Date: Saturday, 29 April 2017

Time: 12:15 – 13:15

Location: Lecture Room Zola

Chairpersons:

M. Petrie (Glasgow, Great Britain)

B. Pitt (Ann Arbor, United States of America)

- 12:15 Health policy and economics related to treatment of fluid overload in heart failure
N. Desai (New Haven, United States of America)
- 12:30 Rationale for a new furosemide product 50 years after its first introduction
R. deBoer (Groningen, Netherlands)
- 12:45 Clinical experience with subcutaneous furosemide in patients with fluid overload
N. Gilotra (Baltimore, United States America)
- 13:00 First experience with a patch infusor for subcutaneous administration of a novel furosemide formulation
J. Udelson (Boston, Unites States of America)

Investigational Product: has not been approved for commercial use by the
United States Food and Drug Administration or any regulatory authority

Sunday, 30, April 2017 | 10:15 – 10:45 | Agora 2

Ask the Experts: Your questions on Furosemide 2.0 and the potential of subcutaneous self-administration

Moderator/Chair: Mark Petrie (GB) and Bertram Pitt (USA)

Expert Panel:

Pieter Muntendam (USA)
Rudolf deBoer (NL)
James Udelson (USA)

SATURDAY, APRIL 29, 2017

12:15 - 13:15 ROOM: RENOIR LEVEL 2

Heart Failure with reduced ejection fraction and narrow QRS: How can baroreflex stimulation help?

CHAIRS

Stefan D. Anker, Göttingen, Germany


Andrew J. Coats, Warwick, UK

SPEAKERS


William T. Abraham, Columbus, OH, USA

Edoardo Gronda, Sesto San Giovanni, Italy

Piotr Ponikowski, Wroclaw, Poland



Organised by Charité Friends
& Sponsors Trust



Supported by an unrestricted
grant provided by



SATURDAY, APRIL **29**, 2017

12:15 - 13:15 ROOM: RENOIR LEVEL 2

PROGRAMME

**Heart Failure with reduced ejection fraction and narrow QRS:
How can baroreflex stimulation help?**

Welcome and Introduction

Chairs

HF guidelines recommendations for special populations – the need for more innovation

Piotr Ponikowski, Wroclaw, Poland

The landscape of reflex control in heart failure

Edoardo Gronda, Sesto San Giovanni, Italy

The Barostim technology and HF trial results

William T. Abraham, Columbus, OH, USA

Panel discussion

EDUCATIONAL
OBJECTIVES

- Understand how specific management strategies can be applied in special populations of patients with heart failure, and specifically autonomic neuromodulation as a therapeutic target
- Review the role of the activation of the sympathetic nervous system in the pathogenesis of heart failure
- Assess the baroreflex as a primary regulator of cardiovascular function
- Review the data and experience with Baroreflex Activation Therapy in Heart Failure with reduced Ejection Fraction (HFrEF)

LUNCHTIME SATELLITE SYMPOSIUM

Novel transcatheter options for functional mitral regurgitation in heart failure

SATURDAY, APRIL 29, 2017

13:30 - 14:30

ROOM: RENOIR LEVEL 2

CHAIRS

Stefan D. Anker, Göttingen, Germany


William T. Abraham, Columbus, OH, USA

SPEAKERS

Piotr Ponikowski, Wrocław, Poland

Stephan von Bardeleben, Mainz, Germany

Alec Vahanian, Paris, France



SATELLITE SYMPOSIUM

Organised by Charité Friends
& Sponsors Trust

Charité

CHARITÉ
UNIVERSITÄT BERLIN

Supported by an
unrestricted
grant provided by



Edwards Lifesciences

SATURDAY, APRIL 29, 2017

13:30 - 14:30

ROOM: RENOIR LEVEL 2

PROGRAMME

Novel transcatheter options for functional mitral regurgitation in heart failure

Welcome and Introduction

Chairs

The clinical problem of functional mitral regurgitation (FMR): what do the guidelines say?

Piotr Ponikowski, Wroclaw, Poland

Imaging of FMR and the selection of therapeutic options

Stephan von Bardeleben, Mainz, Germany

Annular reconstruction therapies: Edwards Cardioband™ mitral repair system

Alec Vahanian, Paris, France

EDUCATIONAL OBJECTIVES

After attending the symposium, participants will be able to

- Review current guidelines regarding the management of functional mitral regurgitation (FMR)
- Discuss the implications of ongoing clinical trials
- Understand the value of imaging in the implementation of optimal treatment strategies for FMR
- Review the data and experience regarding annular reconstruction therapies and particularly the Edwards Cardioband™ mitral repair system

Organised by Charité Friends
& Sponsors Trust



Supported by an
unrestricted
grant provided by



Edwards Lifesciences

LIVING V.S. SURVIVING



SATELLITE SYMPOSIUM

Saturday, 29th April 2017
12:15 - 13:15, Matisse Room

TREATING FUNCTIONAL MITRAL REGURGITATION (FMR) IN HEART FAILURE WITH **TRANSCATHETER** **MITRAL VALVE REPAIR (TMVR):** RENDEZ-VOUS WITH THE FUTURE NOW!

CHAIRPERSONS: *F Ruschitzka (Zurich, Switzerland)*
A. Vahanian (Paris, France)

Introduction

F Ruschitzka (Zurich, Switzerland) & A. Vahanian (Paris, France)

How do we treat Functional Mitral Regurgitation with TMVRepair today?

- **Disease and Diagnosis.** *E Donal (Rennes, France)*
- **When to treat?** *J Seeburger (Leipzig, Germany)*
- **Who and Why to treat?** *C Grasso (Catania, Italy)*

How should we treat Functional Mitral Regurgitation in the future? Discussion.

Safety and effectiveness of the TMVR device have not been established in pediatric patients.

BEAT AS ONE



Recent 2016 ESC Guidelines on Heart Failure stated


“In patients with HF with moderate-severe, secondary mitral regurgitation who are judged inoperable or at high surgical risk, percutaneous mitral valve intervention (percutaneous edge-to-edge repair) may be considered in order to improve symptoms and quality of life, although no RCT evidence of improvement has been published, only registry studies.”¹

Learn more about Who are the patients eligible for **Transcatheter Mitral Valve Repair** on:



Or during our:

SATELLITE SYMPOSIUM
on **Saturday, 29th April 2017**
at **12:15 - 13:15, Matisse Room**



1. Ponikowski P, et al - 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. EHJ2016; 37 (27):2129-2200

Abbott Vascular International BVBA, Park lane, Culliganlaan 2b, 1831 Diegem, Belgium, tel: +32 2 714 14 11 Information contained herein is for international delegates from Europe, Middle East and Africa only. Product is subject to prior training requirement as per the instructions for use. This product is intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for instructions for use, warnings and potential complications associated with the use of this device. All drawings are artist's representations only and should not be considered as an engineering drawing or photograph. Photo(s) on file at Abbott Vascular. All products herein are trademarks of the Abbott Group of Companies. The following should be considered by French health-care professionals only: Clip de réparation mitrale et accessoires. Dispositifs médicaux de classe III et I, organisme notifié BSI. Fabriqué par Evalve Inc, mandataire européen Abbott Vascular BVBA. Se référer aux informations de la notice d'instructions qui décrivent les informations de bon usage du dispositif. Veuillez lire attentivement les instructions figurant dans la notice. Pris en charge par les organismes d'assurance maladie. For more information, visit our website at abbottvascular.com © 2017 Abbott. All rights reserved. 9-EH-2-6637-01 03-2017 Rev. A.





This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.



Organised by Lorraine University
Course Director: Professor Faiez Zannad

EBAC ACCREDITED SATELLITE SYMPOSIUM HELD DURING THE HEART FAILURE 2017 & 4TH WORLD CONGRESS ON ACUTE HEART FAILURE

New Opportunities for an Old Problem: Lowering Potassium to Maximize Heart Failure Therapy

Saturday, April 29th, 2017
13:30–14:30

MATISSE



In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Supported by an unrestricted educational grant from AstraZeneca





This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.



UNIVERSITÉ
DE LORRAINE

Organised by Lorraine University
Course Director: Professor Faiez Zannad

EBAC ACCREDITED SATELLITE SYMPOSIUM HELD DURING THE HEART FAILURE 2017 & 4TH WORLD CONGRESS ON ACUTE HEART FAILURE

New Opportunities for an Old Problem: Lowering Potassium to Maximize Heart Failure Therapy

Learning objectives

By the end of this program, attendees will understand:

- The risk of morbidity and mortality posed by hyperkalemia in patients with heart failure
- The deleterious effects of down-titration of RAAS inhibitor therapy as a result of moderate or recurrent acute hyperkalemia
- The role of novel hyperkalemia therapies to help maintain optimal guideline-recommended therapy for heart failure

Agenda

Time	Session	Presenter
13:30–13:40	Chair's introduction	Faiez Zannad (France)
13:40–14:00	The unseen impact of hyperkalemia: Implication of suboptimal RAAS inhibitor therapy	John Cleland (UK)
14:00–14:20	Managing potassium to optimize therapy for heart failure	Peter van der Meer (Netherlands)
14:20–14:30	Panel Q&A/Discussion	All presenters



In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Supported by an unrestricted educational grant from AstraZeneca



SATELLITE SYMPOSIUM



April 29th 2017
Room: PIAF (level 2)
12:15 – 13:15

UPDATES ON RISK GUIDED STRATIFICATION FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH IN HEART FAILURE

www.gehealthcare.com

Chair: Allen ANDERSON, MD (Chicago, US)

Lars KØBER, MD (Copenhagen, Denmark)

- Updates on Implantable Cardiac Defibrillator (ICD) trials: The Danish study and beyond

Silvia PRIORI, MD (Pavia, Italy)

- Should guidelines be adapted?

Faeiz ZANNAD, MD (Les Nancy, France)

- ¹²³I-iobenguane for Myocardial Imaging for Risk Evaluation: The ADMIRE ICD trial

Roche Satellite Symposium

NT-proBNP: the gold standard biomarker in heart failure

Date: Saturday, 29 April 2017

Time: 13:30 – 14:30

Location: Lecture room PIAF

Co-chairmen

Prof. Dr. James L. Januzzi *Boston, USA*

Prof. Dr. A. Mark Richards *Christchurch, New Zealand*

Visit Roche at exhibition booth A20

*In trusting NT-proBNP at every stage of care,
I can give answers to one. And hope to many.*



Roche Satellite Symposium

NT-proBNP: the gold standard biomarker in heart failure

Agenda

- 13:30 – 13:45 NT-proBNP as initial test in the diagnostic algorithm of heart failure: “the golden hour”
- 13:45 – 14:00 Prognostic value of NT-proBNP for safe and optimized discharge planning: “the golden month”
- 14:00 – 14:15 The influence of sacubitril/valsartan on natriuretic peptides
- 14:15 – 14:30 Q&A

*Prof. Dr. Adriaan Voors
Groningen, The Netherlands*

*Prof. Dr. Alain Cohen-Solal
Paris, France*

*Prof. Dr. Scott D. Solomon
Boston, USA*

*In trusting NT-proBNP at every stage of care,
I can give answers to one. And hope to many.*





Novartis Satellite Symposia
at Heart Failure 2017 &
4th World Congress on
Acute Heart Failure

Contemporary management of patients with HFrEF

12:45–14:00 Sunday 30 April 2017

Hugo Room, Le Palais des Congrès de Paris

Chairs: Faiez Zannad (France) and John McMurray (UK)



Scan QR code or go to www.radcliffecardiology.com/novartis-esc-hf-2017
to view a live stream of the Satellite Symposium or a recorded video after the event

**Turn over the page
to view the full agenda**



This Satellite Symposium is organised and funded by Novartis Pharma AG
© 2017 Novartis Pharma AG, CH-4002 Basel | March 2017 | GLCM/HTF/0341

Novartis Satellite Symposia
at Heart Failure 2017 &
4th World Congress on
Acute Heart Failure

Contemporary management of patients with HFrEF

12:45–14:00 Sunday 30 April 2017
Hugo Room, Le Palais des Congrès de Paris

Chairs: Faiez Zannad (France) and John McMurray (UK)

	Topic	Faculty
12:45–12:48	Welcome and introduction	Faiez Zannad (France) and John McMurray (UK)
12:48–12:58	One year after updating the heart failure guidelines – has the management of patients with HFrEF changed?	John McMurray (UK)
12:58–13:28	Managing contemporary HFrEF therapies – clinical case discussion	Peter van der Meer (The Netherlands)
13:28–13:58	Optimising contemporary HFrEF therapies in patients with comorbidities – clinical case discussion	Frank Ruschitzka (Switzerland)
13:58–14:00	Summary and key learning points	Faiez Zannad (France)

PLUS: Satellite Symposium – Experts on the Spot
Optimising treatment of heart failure – where are we today?


15:55–16:25 Sunday 30 April 2017, Agora 1

Moderator Frank Ruschitzka

Panelists John McMurray and John Teerlink



This Satellite Symposium is organised and funded by Novartis Pharma AG
© 2017 Novartis Pharma AG, CH-4002 Basel | March 2017 | GLCM/HTF/0341



Satellite Symposium

Management of Co-morbidities in Heart Failure – Exploring new frontiers



Management of Co-morbidities in Heart Failure – Exploring new frontiers

Sunday 30 April 2017, 12.45 – 14.00

Palais des Congrès, Paris, France


Room Monet (Level 3, **lunch will be provided**)

Moderated by co-chairs: Nicolas Danchin and Martin Cowie

- | | |
|----------------------|--|
| 12.45 – 12.50 | Introduction
Nicolas Danchin, France |
| 12.50 – 13.05 | Expanding the evidence for Rivaroxaban in AF patients with co-morbidities including HF: From RCT to RWE
Martin Cowie, UK |
| 13.05 – 13.20 | Options in Thrombosis Prevention and Vascular Health – What's on the Horizon?
Keith Fox, UK |
| 13.20 – 13.35 | Broadening the evidence base for Rivaroxaban in Heart Failure
Barry H. Greenberg, USA |
| 13.35 – 13.50 | Exploring new frontiers: Is it time for a comorbidity-based approach in Heart Failure?
Carolyn Lam, Singapore |
| 13.50 – 14.00 | Q&A and closing remarks
Martin Cowie, UK |



Bayer AG
L.FR.COM.02.2017.2722





Satellite Symposium

IMPLANTABLE CARDIAC DEVICE THERAPY FOR HEART FAILURE: UPDATE 2017

Sunday, April 30

12:45 – 14:00 (Room Zola)

Chairmen:

C. Leclercq (Rennes, FR)

G. Filippatos (Athens, GR)

12:45	Introduction	C. Leclercq (Rennes, FR)
12:50	Latest developments in cardiac resynchronizaton therapy	A. Patwala (Newcastle-under-Lyme, GB)
13:10	Left ventricular assist devices for advanced heart failure	N. Aissaoui (Paris, FR)
13:30	A monitoring center for implantable cardiac devices	S. Allen (Manchester, GB)
13:50	Conclusions	G. Filippatos (Athens, GR)

Medtronic
Further. Together

**YOUR PARTNER
IN HEART FAILURE MANAGEMENT
OFFERING INNOVATIVE
SOLUTIONS FOR PATIENTS
ACROSS THE CONTINUUM OF CARE**



Come and see us at **Booth C35**

Learn more about our technology, services and solutions at www.medtronic.eu.

UC201709563EE © 2017 Medtronic. All rights reserved.

Medtronic
Further, Together



SUNDAY, APRIL 30, 2017

12:45 - 13:45

ROOM: RENOIR

LEVEL 2

A mitochondrial approach to heart failure



CHAIRS

Stefan D. Anker, Göttingen, Germany

John Cleland, London, UK

SPEAKERS

Andrew J. Coats, Warwick, UK

Bertram Pitt, Ann Arbor, MI, USA

Brian Stauffer, Denver, CO, USA

Organised by Charité Friends
& Sponsors Trust



Supported by an unrestricted
grant provided by



Leading
Mitochondrial
Medicine

SATELLITE SYMPOSIUM

SATELLITE SYMPOSIUM

SUNDAY, APRIL 30, 2017 • 12:45 - 13:45 • ROOM: RENOIR

LEVEL 2

A mitochondrial approach to heart failure

PROGRAMME

Mitochondrial function as a therapeutic target in heart failure

Andrew J. Coats, Warwick, UK

Elamipretide improves mitochondrial activity in the failing human heart

Brian Stauffer, Denver, CO, USA

Targeting multi-organ dysfunction in heart failure: a mitochondrial approach


Bertram Pitt, Ann Arbor, MI, USA

Panel discussion

EDUCATIONAL OBJECTIVES

- > Review the role of mitochondrial function in the pathogenesis of heart failure
- > Assess mitochondrial involvement in myocyte death and heart failure
- > Review new therapeutic modalities that target mitochondrial abnormalities in heart failure
- > Focus on Elamipretide as a new therapeutic tool to improve mitochondrial structure and function
- > Discuss innovative approaches to target multi-organ dysfunction in heart failure

Organised by Charité Friends
& Sponsors Trust



Supported by an unrestricted
grant provided by



Leading
Mitochondrial
Medicine

Heart Failure 2017 & 4th World Congress on Acute Heart Failure

Palais des Congrès de Paris, Paris, France



SATELLITE SYMPOSIUM

Sunday 30 April 2017, 12:45–14:00, Matisse room

Iron Deficiency in Patients with Heart Failure: Time for Action

Time	Session	Faculty
12:45–12:50	Welcome and Introduction	Alain Cohen-Solal (France)
12:50–13:05	Burden and Impact of Iron Deficiency in Heart Failure	Carolyn Lam (Singapore)
13:05–13:25	Current Evidence for the Treatment of Iron Deficiency in Heart Failure	Dirk van Veldhuisen (The Netherlands)
13:25–13:45	Future Directions for the Treatment of Iron Deficiency in Heart Failure	Piotr Ponikowski (Poland)
13:45–14:00	Panel Discussion and Close	Alain Cohen-Solal (France) (moderator)

Lunch to be provided



SAVE THE DATE

Heart Failure 2017 & 4th World Congress on Acute Heart Failure

Palais des Congrès de Paris, Paris, France



SATELLITE SYMPOSIUM – EXPERTS ON THE SPOT
Monday 1 May 2017, 10:15–10:45, Agora 2 room

Iron Deficiency in Patients with Heart Failure: Implementing the Guidelines in your Clinical Practice

An interactive discussion with leading experts on the treatment of iron deficiency in heart failure.

Experts: Stefan Anker (Germany), Peter van der Meer (The Netherlands), Theresa McDonagh (United Kingdom)



SATELLITE SYMPOSIUM

Beat As One[™]: a multidisciplinary approach to treating heart failure

**WITH AN UNRESTRICTED
EDUCATIONAL GRANT
FROM ABBOTT**

WHEN **Sunday 30 April, 2017**
12:45-13:45

WHERE **Palais des Congrès, Paris**
Level 2 - Room Piaf

CHAIRS **Prof. Ponikowski** (Poland)
Prof. Mullens (Belgium)

AGENDA	12:45-13:00	The Heart Failure Association guidelines for device treatment. Prof. Ponikowski (Poland)
	13:00-13:15	Cardiac resynchronization therapy: getting the best out of the machine! Prof. Mullens (Belgium)
	13:15-13:30	Continuous pulmonary artery pressure monitoring for the treatment of heart failure. Prof. Assmus (Germany)
	13:30-13:45	Mechanical circulatory support: stepping into the limelight Prof. Uriel (U.S.)

© 2017 Abbott. All Rights Reserved. Unless otherwise specified, all product and service names appearing herein are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress may be made without the prior written authorization of Abbott.

EM-ESC-0117-0027 | Item approved for international use only.



**ST. JUDE MEDICAL
IS NOW ABBOTT**



Abbott



Safety at heart

Come and join our Abiomed® Satellite Symposium:

Sunday 30 April 2017

18:15 – 19:15

Lecture Room: PIAF

How innovative pVAD systems improve outcomes in Cardiogenic Shock and facilitate complete revascularization in High Risk PCI patients



- Science of hemodynamics & clinical relevance
- The role of ventricular unloading in heart recovery
- Early patient selection improves outcomes in cardiogenic shock
- Hemodynamic stabilization to facilitate complete revascularization

The Wearable Cardioverter Defibrillator: An essential tool in the management of patients at high risk for sudden cardiac death

HEART FAILURE 2017 AND 4TH WORLD CONGRESS ON ACUTE HEART FAILURE
PARIS/ FRANCE, 29 APRIL–2 MAY 2017

LUNCH SATELLITE SYMPOSIUM

1 May 2017 • 12:45–14:00 • Room Hugo, Level 2

Chairpersons

Pr. Christophe Leclercq
CHU de Rennes/ France

Dr. Thomas M. Helms
*Peri Cor Cardiology
Working Group,
Hamburg/ Germany*

Speakers

PD Dr. Christian Veltmann
*Medizinische Hochschule
Hannover/ Germany*

PD Dr. Johannes Sperzel
*Kerckhoff-Klinik
Bad Nauheim/ Germany*

Prof. Dr. Stefan Stoerk
*Universitaetsklinikum
Wuerzburg/ Germany*

Program overview

Managing sudden cardiac death risk is critical during the early period after a new diagnosis of heart failure or non-ischemic cardiomyopathy. This program will discuss recent data from the PROLONG study and DANISH trial and the management of these patients. The faculty will also discuss the implementation of effective screening processes in order to identify the right patient at SCD risk in your hospital, and the utility of patient management monitoring systems to effect better outcomes for newly diagnosed heart failure patients.

The Wearable Cardioverter Defibrillator: An essential tool in the management of patients at high risk for sudden cardiac death

**HEART FAILURE 2017 AND
4TH WORLD CONGRESS
ON ACUTE HEART FAILURE**

PARIS/ FRANCE
29 APRIL–2 MAY 2017

SATELITTE SYMPOSIUM

1 May 2017

12:45–14:00

Room Hugo, Level 2

© 2017 ZOLL Medical Corporation. ZOLL and LifeVest
are registered trademarks of ZOLL Medical Corporation
in the United States and/or other countries.

20c0677_revfi

Agenda

-
- | | |
|-------|--|
| 12:45 | Introduction
Dr. Thomas Helms, <i>Hamburg/ Germany</i> |
|-------|--|
-
- | | |
|-------|---|
| 12:50 | Current treatment strategies for newly
diagnosed heart failure patients
PD Dr. Christian Veltmann, <i>Hannover/ Germany</i> |
|-------|---|
-
- | | |
|-------|---|
| 13:10 | Screening: A systematic and efficient way
to optimize patient selection at risk for
sudden cardiac death
PD Dr. Johannes Sperzel, <i>Bad Nauheim/ Germany</i> |
|-------|---|
-
- | | |
|-------|--|
| 13:30 | Utility of remotely managed patient
clinical and diagnostic markers to effect
better outcomes
Prof. Dr. Stefan Stoerk, <i>Wuerzburg/ Germany</i> |
|-------|--|
-
- | | |
|-------|---|
| 13:50 | Panel discussion and summary
Pr. Christophe Leclercq, <i>Rennes/ France</i> |
|-------|---|
-

ZOLL® LifeVest®



This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity.



Organised by:
University Medical Center Groningen
Course Director:
Prof.dr. Adriaan A Voors

EBAC ACCREDITED SATELLITE SYMPOSIUM TO BE HELD DURING HEART FAILURE 2017, PARIS, FRANCE

**Don't miss the complementary
'EBAC Accredited Educational
Programme – Experts on
the Spot' session
scheduled on Tuesday May 2,
15:55 – 16:25 Agora 2**

Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach

MONDAY, MAY 1, 2017; 12:45 – 13:45 HRS, MONET

IN CO-OPERATION WITH



Physicians' Academy
for Cardiovascular Education

Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

"In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities."



EBAC Accredited satellite symposium to be held during Heart Failure 2017, Paris, France

Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach

MONDAY, MAY 1, 2017; 12:45 – 13:45 HRS

AGENDA

- 12:45 – 12:50 **Introduction**
Adriaan Voors, MD – UMCG, Groningen, The Netherlands
- 12:50 – 13:05 **Challenges in Heart Failure management: Diabetes and Renal Impairment**
Martin Cowie, MD – Imperial College London, London, United Kingdom
- 13:05 – 13:25 **SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome**
Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland
- 13:25 – 13:45 **New diabetes drugs and heart failure: What have we learnt?**
John McMurray, MD – University of Glasgow, United Kingdom

Educational objectives

- Emphasize heart failure as a disease in which innovation is ongoing, yielding several new agents that are soon likely to change clinical practice
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and heart failure and the particular risk of patients with diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
- To provide an expert perspective on the role of SGLT2 inhibitors in the treatment of patients with diabetes and heart failure
- To discuss current and future strategies for practical management of heart failure and interventions to prevent cardiovascular events

For information please visit the Physicians' Academy for Cardiovascular Education (PACE) foundation at **www.pace-cme.org**

Heart Failure: What is the Potential of SGLT2 Inhibition?

Monday, May 1st, 2017

12:45–13:45

ZOLA



This Non-Promotional Satellite Symposium is organised and funded by AstraZeneca © 2017
ATLAS ID: 1,033,434.011 Date of preparation: February 2017 Date of expiry: February 2018

AstraZeneca 
What science can do

Heart Failure:

What is the Potential of SGLT2 Inhibition?

Despite the growing treatment landscape and improvements in other CV outcomes, mortality rates from heart failure have not improved for decades. This symposium explores the potential of SGLT2 inhibitors in the treatment landscape for heart failure.

Session	Speaker	Time
Chair's introduction	Simon Williams, UK	12:45–12:50
The ongoing problem of heart failure	John McMurray, UK	12:50–13:10
Q&A	Simon Williams, UK John McMurray, UK	13:10–13:15
SGLT2 inhibition: The potential to change the heart failure landscape?	Mikhail Kosiborod, USA	13:15–13:35
Q&A	Simon Williams, UK Mikhail Kosiborod, USA	13:35–13:40
Summary and close	Simon Williams, UK	13:40–13:45



LUNCHTIME SATELLITE SYMPOSIUM

MONDAY, MAY 1st, 2017 • 12:45 - 13:45 • ROOM: RENOIR LEVEL 2

Tricuspid Regurgitation in heart failure: how to treat it?

CHAIRS

William T. Abraham
Columbus, OH, USA

Andrew J. Coats
Coventry, UK

SPEAKERS

Stefan D. Anker
Göttingen, Germany

Louis Labrousse
Pessac, France

Azeem Latib
Milan, Italy

Organised by Charité Friends
& Sponsors Trust

Charité

CHARITÉ
UNIVERSITÄT MEDIZIN BERLIN

Supported by an unrestricted
grant provided by

mitralign

MONDAY

MAY 1ST, 2017

12:45 - 13:45

ROOM: RENOIR LEVEL 2

PROGRAMME

Tricuspid Regurgitation in heart failure: how to treat it?

Tricuspid regurgitation in the heart failure population

Stefan D. Anker, Göttingen, Germany

Surgical techniques to treat tricuspid regurgitation –
the Kay procedure and other approaches

Louis Labrousse, Pessac, France

Transcatheter repair for functional tricuspid
regurgitation: first clinical trial results for the Trialign
system

Azeem Latib, Milan, Italy

Panel discussion



EDUCATIONAL OBJECTIVES

- > Review the burden of Tricuspid Regurgitation (TR) in patients with heart failure
- > Discuss the role of surgical interventions in the management of TR
- > Focus on transcatheter repair for functional TR
- > Discover the first clinical trial results for the Trialign system

Organised by Charité Friends
& Sponsors Trust



Supported by an unrestricted
grant provided by



Heart Failure 2017 & 4th World Congress on Acute Heart Failure, Paris

Enabling and optimizing RAASi therapy in
cardio-renal patients by controlling potassium levels

Satellite Symposium*

Monday 1 May 2017, 12:45 – 14:00
Room Matisse

Satellite Symposium – Experts on the Spot

Monday 1 May 2017, 15:55 – 16:25
Room Agora 1

*Lunch will be provided

 Vifor Pharma

 Vifor Fresenius Medical Care
Renal Pharma 

Satellite Symposium*

Enabling and optimizing RAASi therapy in cardio-renal patients by controlling potassium levels

Chairs: Faiez Zannad (France), Bertram Pitt (USA)

Monday 1 May 2017, 12:45 – 14:00, Room Matisse

Time	Session	Speaker
12:45 - 12:50	Welcome and introduction	Bertram Pitt, USA
12:50 - 13:05	RAASi therapy benefit and challenges in cardio-renal patients	Lars Lund, Sweden
13:05 - 13:20	Treatment strategies to manage hyperkalaemia and control potassium levels	Stefan Anker, Germany
13:20 - 13:35	Changing the treatment paradigm of hyperkalaemia management to enable and optimize RAASi therapy	Javed Butler, USA
13:35 - 13:55	Panel discussion with Q&A	Bertram Pitt, USA
13:55 - 14:00	Summary and close	Faiez Zannad, France

*Lunch will be provided

Satellite Symposium – Experts on the Spot

Enabling and optimizing RAASi therapy in cardio-renal patients by controlling potassium levels

Chair: Bertram Pitt (USA)

Speakers: Michael Böhm (Germany), Carolyn Lam (Singapore)

Monday 1 May 2017, 15:55 - 16:25, Room Agora 1



**FRESENIUS
MEDICAL CARE**

Heart Failure and 4th World Congress on Acute Heart Failure
29 April–2 May 2017 · Paris, France


Lunch provided

Satellite Symposium: Fresenius Medical Care

Monday 1st May 2017

12:45–13:45

Lecture Room: Piaf

Understanding congestion: Thinking beyond diuretic therapy



Frank Ruschitzka
Switzerland



Gerasimos Filippatos
Greece



Marco Metra
Italy



Piotr Ponikowski
Poland



Maria Rosa Costanzo
USA





Understanding congestion: Thinking beyond diuretic therapy

Co-chairs: Frank Ruschitzka and Gerasimos Filippatos

Faculty: Maria Rosa Costanzo, Piotr Ponikowski, Marco Metra

12.45 – 12.49 Welcome and introduction

(Frank Ruschitzka – Switzerland and Gerasimos Filippatos – Greece)

12.49 – 13.01 Congestion – the key target in the treatment of decompensated heart failure

(Marco Metra – Italy)

13.01 – 13.13 The decongestion toolkit: Restoring sensitivity to diuretics

(Piotr Ponikowski – Poland)

13.13 – 13.25 Peripheral ultrafiltration: Exploring new options for acutely decompensated heart failure

(Maria Rosa Costanzo – USA)

13.25 – 13.40 Panel discussion and Q&A

(Facilitated by Frank Ruschitzka – Switzerland and Gerasimos Filippatos – Greece)

13.40 – 13.45 Key takeaways

(Frank Ruschitzka – Switzerland)



**Sunday, 30th April
& Monday, 1st May 2017**
Hands-On Room 1

With the participation of
GE Healthcare

HANDS-ON TUTORIALS

You Want To:

- Understand how you can optimize Mitral Regurgitation treatment with Transcatheter Mitral Valve Repair (TMVR) in Heart Failure patients: from diagnosis to follow-up
- Interact with Transcatheter Mitral Valve Repair device and Transthoracic Echocardiographic Ultrasound system
- Understand how a ramp study can be used to optimize device settings on a left ventricular assist device (LVAD)
- See and interact with a demonstration of a ramp study on a patient with a left ventricular assist device (LVAD)

BEAT AS ONE



With the participation of
GE Healthcare

TMVR SESSION

- 45 min: TREATING MITRAL REGURGITATION IN HEART FAILURE PATIENT: FROM DIAGNOSIS TO FOLLOW-UP Prof. E. Donal, Rennes, FR
- TRANSCATHETER MITRAL VALVE REPAIR: DEVICE & SCREENING HANDS-ON

30 min: How To Assess Mitral Valve And Mitral Regurgitation With Transthoracic Echocardiographic Ultrasound Dr O. Lairez, Toulouse, FR

30 min: Transcatheter Mitral Valve Repair Device
D. Van Hees, SH Training Manager, Abbott Vascular

LVAD SESSION

- 40 min: USING RAMP STUDIES IN ASSIST DEVICE PATIENTS: THEORY AND EVIDENCE Prof. Nir Uriel, Chicago, US
- 50 min: LEFT VENTRICULAR ASSIST VENTRICULAR DEVICE: PERFORMING A RAMP STUDY USING ECHOCARDIOGRAPHIC GUIDANCE

30 attendees max.

To book your place:

Please pass by the room or email emea.sh@av.abbott.com or text your name & schedule of your choice +32 478 91 06 28

Learn more on:



JOIN THE FOLLOWING SESSIONS THAT INCLUDE:

SUNDAY 30/04:

Session TMVR 1: 08:30 - 10:30
Session TMVR 2: 11:00 - 13:00
Session TMVR 3: 14:00 - 16:00
Session LVAD: 16:30 - 18:00

MONDAY 1/05:

Session TMVR 1: 08:30 - 10:30
Session TMVR 2: 11:00 - 13:00
Session TMVR 3: 14:00 - 16:00
Session LVAD: 16:30 - 18:00

Abbott Vascular International BVBA, Park lane, Culliganlaan 2b, 1831 Diegem, Belgium, tel: +32 2 714 14 11
Information contained herein is for international delegates from Europe, Middle East and Africa only.
For more information, visit our website at abbottvascular.com © 2017 Abbott. All rights reserved.
9-EH-2-6644-01 02-2017





WELCOME TO HANDS-ON TUTORIALS ON INODILATION

The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data has been collected on the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel opener levosimendan have been proposed as a safer inodilator.¹ This series of tutorials focus on how to use safely and effectively levosimendan in acute and advanced heart failure.



Sunday, 30 April and Monday, 1 May 2017 09:00 -10:30

Hands-On Room 2

Repetitive use of Inodilators in Advanced Heart Failure

CHAIRS: Johann Altenberger (Salzburg, Austria), Gerhard Pözl (Innsbruck, Austria)

9:00 **The rationale** // Johann Altenberger (Salzburg, Austria)

9:30 **The scientific evidence** // Gerhard Pözl (Innsbruck, Austria)

10:00 **The clinical practice** // Gabriella Malfatto (Milano, IT)

Sunday, 30 April and Monday, 1 May 2017 11:15 -12:45 Hands-On Room 2

Inotropes or inodilators in HFrEF: what to use, on whom, when and how?

CHAIRS: Veli-Pekka Harjola (Helsinki, Finland), Zoltan Papp (Debrecen, Hungary)

11:15 **What is available?** // Zoltan Papp (Debrecen, Hungary)

11:45 **The therapeutic needs** // Veli-Pekka Harjola (Helsinki, Finland)

12:15 **The clinical practice** // Kristjan Karason (Gothenburg, Sweden)

Sunday, 30 April and Monday, 1 May 2017 14:00 -15:30 Hands-On Room 2

Inodilators and renal function: How to avoid kidney dysfunction in AHF

CHAIRS: Finn Gustafsson (Copenhagen, Denmark), John Parissis (Athens, Greece)

14:00 **Cardiorenal syndrome**
// Detlef Kindgen-Milles (Dusseldorf, Germany)

14:30 **Therapeutic options: what, when and why**
// John Parissis (Athens, Greece)

15:00 **How to avoid kidney dysfunction in AHF** // Finn Gustafsson (Copenhagen, Denmark)

Sunday, 30 April and Monday, 1 May 2017 16:15 -17.45 Hands-On Room 2

Inotropes in Acute Heart Failure: from guidelines to practical use

CHAIRS: Fabrizio Oliva (Milano, Italy), Carsten Tschöpe (Berlin, Germany)

16:15 **The ESC Guidelines in practice** // Matti Kivikko (Espoo, Finland)

16:45 **Patients in need of inotropes** // Carsten Tschöpe (Berlin, Germany)

17:15 **How to treat such patients** // Fabrizio Oliva (Milano, Italy)

Refreshments will be served at each session.

The same program with same timings will be held both on Sunday, 30 April and Monday, 1 May 2017.

Ref. 1. Pollesello P et al. Int J Cardiol. 2016;203:543-8



ALERE HANDS-ON TUTORIAL AT HEART FAILURE 2017 & 4TH WORLD CONGRESS ON ACUTE HEART FAILURE.

The Alere team invites you to a Hands-On Tutorial at the Alere Forum (Hands-on Room 3, Le Palais des Congrès de Paris).

Sunday, 30 April 3.00 – 5.00pm

Monday, 1 May 3.00 – 5.00pm

Please join us to find out how Near to Patient Testing can provide clinical, operational and economic benefits. In this Hands-on Tutorial we will demo our point-of-care solutions for Heart Failure, Acute Coronary Syndrome, Diabetes, and Blood Gas Testing. Come and get your own results!

Find us at booth #B80 on Level 2.

Sunday, 30 April 1.00 – 2.30pm

Time is muscle in acute heart failure: diagnose, treat and prevent!

This is a Lunch & Learn Session about the time to therapy concept for acute heart failure, which is now recommended by the new ESC guidelines. How can the journey of those patients be managed in daily practice?

Monday, 1 May 1.00 – 2.30pm

Best practice for discharge and follow up of patients hospitalised with acute heart failure: role of natriuretic peptides and point-of-care testing.

Acute heart failure patients still experience a high readmission and mortality rate after discharge. In this Lunch & Learn Session experiences will be shared on how to improve the outcome of these patients with proper discharge planning and follow up management.

Find us at booth #B80 on Level 2 to register your attendance.

Speakers

Christian Müller

Department of Cardiology
Cardiovascular Research Institute Basel (CRIB)
University Hospital, Basel, Switzerland

Massimo Iacoviello

Cardiology Unit, Cardio-Thoracic Department
Policlinic of Bari, University of Bari, Italy

Speakers

Kenneth McDonald

Department of Cardiology, St Vincent's
University Hospital, Dublin, Ireland

Patrick Jourdain

Heart Failure Unit CHR Dubos
Pontoise Hospital, Pontoise, France

Organised by the Heart Failure Association of the ESC

HEART FAILURE | 2018

including the World Congress on Acute Heart Failure

26-29 MAY

VIENNA

Heart Failure: classical repertoire,
modern instruments



HEART FAILURE
ASSOCIATION
OF THE ESC



EUROPEAN
SOCIETY OF
CARDIOLOGY

www.escardio.org/heartfailure



Join us and discover the
world of a HFrEF patient.

ACTIVATE THE HEART^{*}

ACTIVATE LIFE^{1,2}

ENTRESTO[®] keeps your symptomatic HFrEF patients living longer and out of the hospital³

- **20% reduced risk** of CV death or first HF hospitalisation vs enalapril ($P < 0.0001$; ARR = 4.7%)^{3†}

ENTRESTO[®] helps improve Quality of Life⁴

- **Significant improvements in Quality of Life** vs enalapril, as measured by reduced deterioration of heart failure symptoms and physical limitations ($P = 0.001$)^{4‡}

When you see symptoms,
IT'S TIME FOR ENTRESTO³



Please see Summary of Product Characteristics at Booth B30.

▼ This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

ARR = absolute risk reduction; CV = cardiovascular; HF = heart failure; HFrEF = heart failure with reduced ejection fraction.

*The complementary cardiovascular benefits of ENTRESTO in patients with HFrEF are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by sacubitril and the simultaneous inhibition of the deleterious effects of angiotensin II by valsartan.

† Primary end point.

‡ Secondary end point that measured the change from baseline to 8 months in the clinical summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ).

References: 1. Fala L. Entresto (sacubitril/valsartan): First-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. *Am Health Drug Benefits*. 2015;8(6):330-334. 2. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. *Clin Sci*. 2016;130(2):57-77. 3. ENTRESTO Summary of Product Characteristics. European Medicines Agency, 2016. <http://www.ema.europa.eu>. 4. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371(11):993-1004.